Technical Analysis for XGN - Exagen Inc.

Grade Last Price % Change Price Change
grade D 12.95 -0.38% -0.05
XGN closed down 0.38 percent on Wednesday, October 16, 2019, on 60 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Down
See historical XGN trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Hot IPO Pullback Bullish Swing Setup -0.38%
Inside Day Range Contraction -0.38%
New 52 Week Closing Low Bearish 2.70%
Hot IPO Pullback Bullish Swing Setup 2.70%
New 52 Week Low Weakness 2.70%
Down 3 Days in a Row Weakness 2.70%
Down 4 Days in a Row Weakness 2.70%

Older signals for XGN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Exagen Inc. operates as a commercial-stage diagnostics company, develops and markets products for the diagnosis, prognosis, and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). Its lead product includes Avise SLE+CT, a proprietary diagnostic test that provides an enhanced solution for patients with a range of ARDs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, and scleroderma, as well as other disorders, including fibromyalgia. The company also offers Avise SLE Prognostic, a blood test that complements Avise SLE+CT; Avise MTX, a therapeutic drug monitoring test to measure levels of methotrexate polyglutamates; and Avise HCQ, a blood test for physicians to monitor blood levels of HCQ. In addition, it is developing Anti-TNF, a blood test to monitor the levels of anti-TNF bioactivity in patients with RA; Avise SLE Monitoring, a multi-analyte panel blood test for physicians to track the disease status of their SLE patients; and Avise RA, a blood test to determine bone damage or joint erosion. The company primarily serves rheumatologists in the United States. It was formerly known as Exagen Diagnostics, Inc. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Medicine Medical Specialties Clinical Medicine Immunology Disease Autoimmune Diseases Disorders Rheumatoid Arthritis Autoimmunity Rheumatology Fibromyalgia Scleroderma Sjögren's Syndrome Sle Systemic Lupus Erythematosus
Is XGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 19.5
52 Week Low 11.54
Average Volume 77,645
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 14.703
10-Day Moving Average 13.495
Average True Range 1.224
ADX 0.0
+DI 7.4949
-DI 24.6229
Chandelier Exit (Long, 3 ATRs ) 15.828
Chandelier Exit (Short, 3 ATRs ) 15.212
Upper Bollinger Band 17.953
Lower Bollinger Band 11.453
Percent B (%b) 0.23
BandWidth 44.208665
MACD Line -0.9442
MACD Signal Line -0.6176
MACD Histogram -0.3265
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.64
Resistance 3 (R3) 13.58 13.30 13.53
Resistance 2 (R2) 13.30 13.12 13.33 13.49
Resistance 1 (R1) 13.12 13.01 12.98 13.18 13.45
Pivot Point 12.84 12.84 12.77 12.87 12.84
Support 1 (S1) 12.66 12.66 12.52 12.72 12.45
Support 2 (S2) 12.38 12.55 12.41 12.41
Support 3 (S3) 12.20 12.38 12.38
Support 4 (S4) 12.26